Clinical HIGHLIGHTS

REVIEW
Prostaglandin regulation of type 2 inflammation: From basic biology to therapeutic interventions

Oyebola O. Oyesola and Elia D. Tait Wojno

Department of Immunology, University of Washington, Seattle, WA, 98117, USA

Type 2 immunity is critical for the protective and repair responses that mediate resistance to parasitic helminth infection. This immune response also drives aberrant inflammation during atopic diseases. Prostaglandins are a class of critical lipid mediators that are released during type 2 inflammation and are integral in controlling the initiation, activation, maintenance, effector functions, and resolution of Type 2 inflammation. In this review, we explore the roles of the different prostaglandin family members and the receptors they bind to during allergen- and helminth-induced Type 2 inflammation and the mechanism through which prostaglandins promote or suppress Type 2 inflammation. Furthermore, we discuss the potential role of prostaglandins produced by helminth parasites in the regulation of host-pathogen interactions, and how prostaglandins may regulate the inverse relationship between helminth infection and allergy. Finally, we discuss opportunities to capitalize on our understanding of prostaglandin pathways to develop new therapeutic options for humans experiencing Type 2 inflammatory disorders that have a significant prostaglandin-driven component including allergic rhinitis and asthma.

Keywords: Host-pathogen interactions · Prostaglandins · Therapies · Type 2 inflammation

Introduction

Type 2 immunity is important in the generation of protective immune responses that drive worm clearance during helminth parasite infection as well as for the repair and regenerative process that occurs following infection [1,2]. On the other hand, unnecessary Type 2 immune activation in response to innocuous environmental antigens, such as pollen, food antigens, hair, and animal danders, causes chronic allergic inflammation and tissue damage during allergic diseases such as asthma and atopic dermatitis [2]. Fibrotic Type 2 responses also occur during chronic helminth infection, leading to pathology and loss of tissue function, as seen in chronic infection by Schistosoma species [3]. Furthermore, the antagonistic effect of Type 2 immunity on Type 1 immune activation can decrease the efficacy of protective immune responses against bacterial and protozoan pathogens [4,5] and tumors [2]. More recently, Type 2 immunity has been shown to be important in tissue homeostasis, with key Type 2 immune cells central to barrier maintenance, thermoregulation, tissue adiposity, and metabolism [6–11]. Thus, the Type 2 immune response is integral in steady-state physiology and protection against parasitic worm infection, while aberrant Type 2 responses lead to allergic disease, tissue fibrosis, and increased susceptibility to pathogen exposure and tumor growth. As such, studies that increase our understanding of the factors that regulate Type 2 immune responses have major translational potential.

The Type 2 immune response involves different phases, starting with the sensing of the stimuli and initiation of the immune response via the release of a diverse array of biochemical factors and danger signals [10,12]. These events set the stage for activation and recruitment of cardinal Type 2-associated immune cells and production of Type 2 cytokines and growth factors. This response culminates in the emergence of altered tissue physiology and host–effector responses such as the characteristic “weep and sweep response” [1,2]. Finally, a resolution phase develops that limits the activation of inflammatory cells and helps to promote tissue repair [2]. Lipid mediators such as prostaglandins...
have important functions during the different phases of Type 2 inflammation—initiation, activation and recruitment of cells, the effector phase, and the resolution phase of the response. These factors are enriched in inflamed tissues and are thought to tightly regulate local events that dictate the outcomes of inflammation [13]. While a large body of literature focuses on how cytokines guide Type 2 inflammatory activities [1], in this review, we will turn a spotlight on recent literature that illustrates the critical roles that prostaglandins play in the regulation of Type 2 immune responses.

Basic prostaglandin biology and metabolism

Bioactive lipid mediators include the eicosanoid leukotrienes, lipoxins, and prostaglandins that are released under Type 2 and other inflammatory conditions [14–18]. Studies in both mice and humans have shown that these lipids play a crucial role in all aspects of Type 2 immunity including in the promotion and regulation of Type 2 inflammation [14–19] and associated tissue repair [20,21]. Key among these bioactive lipid mediators are prostanooids, which include prostaglandin (PG)D2, PGE2, PGF2α, PGI2, and thromboxane A2 (TXA2). These factors bind to various G-coupled protein receptors to induce a suite of pleiotropic functions that are dictated by the type of inflammation, the timing, the specific receptor engaged, and the disease context [14,22–29].

Production of most eicosanoids starts with cyclic oxidation of polyunsaturated fatty acids such as arachidonic acids (AAs) and linoleic acids, released from membrane phospholipids [14–16,30,31]. Eicosanoid production occurs in response to epithelial cell-derived cytokines, tissue damage, exposure to antigens and crosslinking of Fc receptors in various immune cells including mast cells, macrophages, and Th2 lymphocytes [31–37]. In addition, other cell types, including parenchymal and epithelial cells, such as tuft cells, have also been shown to have enzymes important for the synthesis of PGD2 [38–44], and a wide array of cell types have been described to produce PGE2 and other prostanooids [45–48]. Activation of phospholipase (PLA) enzymes (mostly PLA2) is important in the release of free fatty acids including AAs from the membrane phospholipid stores into the cytosol for metabolism [22]. For prostanooid production (prostaglandins and thromboxane), AAs are metabolized through the cyclooxygenase (COX) pathway by COX enzymes, which are bifunctional and act in a successive manner to catalyze the bioxyxgenation and cyclization of released AA to form PGG2 as well as the peroxydation of PGG2 to PGH2 [13,26]. There are two main isoforms of COX enzymes, COX-1 and COX-2. COX-1 is constitutively expressed with a housekeeping homeostatic role, and COX-2, the inducible COX, is important in activating processes during inflammation [49]. Formation of active prostanooids then occurs through conversion of PGH2 by various synthases, such as prostaglandin D synthase (PGDS), prostaglandin E synthase (PGES), prostaglandin F synthase (PGFS), prostaglandin I2 synthase (PGIS), and thromboxane A synthase (TXAS), that synthesize PGD2, PGE2, PGF2α, PGI2 (also known as prostacyclin), and TXA2, respectively [47,50–55] (Fig. 1).

During Type 2 inflammation at mucosal surfaces, the full scope of the roles that individual prostaglandins play is not currently well defined. Indeed, some studies have shown contrasting results when studying the significance of different prostaglandins and their receptors, in some cases dependent upon tissue site and disease state [22,56]. Some studies have utilized manipulation of the COX pathway upstream of the prostanoid synthesis pathways to extrapolate conclusions related to the effects of individual prostanooids, in some cases generating results that are difficult to interpret [57–62]. Therefore, a better understanding of the role of the individual prostaglandins still needs to be developed. To do so, chemical or genetic manipulation of the individual prostaglandin pathways and their associated receptors must be employed. To this end, we focus on and explore the different roles of the individual prostanoid family members during Type 2 inflammation.

Prostaglandin D2

PGD2 is one of the products of the prostaglandin synthesis pathway, synthesized as a result of the conversion of the direct precursor PGH2 to PGD2 by PGDS. PGD2 is produced in immune cells, with mast cells proposed as one major source of this eicosanoid [31,63,64]. Other immune cells, like Th2 cells, basophils, macrophages and ILC2s, can also produce PGD2 [32,37,65–67]. In addition, nonimmune cells, like tuft cells [41–44,68–70], mesenchymal cells [71], and stromal cells [72], are potential sources of PGD2. PGD2 binds to the G-protein coupled receptors DP1 and chemoattractant-receptor homologous molecule expressed on Th2 cells (CRTH2, also known as DP2). DP1 was the first receptor identified for PGD2 and is expressed by vascular smooth muscle, platelets, eosinophils, and DCs [73–75]. DP1 engagement has well-characterized effects in mediating vasodilatation, inhibiting platelet aggregation, and modulating production of cytokines in DCs [73]. CRTH2 is expressed preferentially by Th2 lymphocytes, eosinophils, ILC2s, basophils, and small intestinal epithelial cells and binds to PGD2 and some downstream derivatives [70,76–78] (Table 1).

Studies in both humans and mice have shown that PGD2 is found in most tissues in the steady state and is involved in regulation of homeostatic functions in the body. These include regulation of sleep pattern, body temperature, hormone release, and modulation of odor and pain responses, among others [124]. However, this eicosanoid also plays an important role in the regulation of immune responses during Type 2 inflammation. For example, most studies have generally shown an increase in PGD2 levels in various Type 2 inflammatory contexts [70,125–128], although there are few studies, such as during helminth infection of mice with *Brugia malayi* in the lungs, in which PGD2 levels can also be decreased during Type 2 inflammation [129]. Additionally, one key study has compared the relative production of PGD2 and other prostanooids in murine models of allergic disease versus helminth infection [67]. Henkel et al. showed that more PGD2
**Table 1. Prostanoid sources, receptors, and functions in Type 2 inflammation**

| Lipid     | Cellular source                                                                 | Receptor | Cells expressing the receptor                                                                 | Effector function                                                                 |
|-----------|---------------------------------------------------------------------------------|----------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| **PGD<sub>2</sub>** | Mast cells [31,63,64], Th2 cells [32], Basophils [65], ILC2s [66], Tuft cells [41–44,68,69], Macrophages [67], Stromal cells [72], Mesenchymal cells [71] | CRTH2 [73] | Eosinophils [76, 77, 79], Basophils [76,77,80], ILC2s [78,81], Th2 helper cells [76,77], Bronchial epithelial cells [82,83] | Chemotaxis [73, 76, 77, 79], Degranulation [80], Type 2 cytokine production [76,77,81], Epithelial cell migration, differentiation and epithelial cell integrity [82,83] |
|           |                                                                                | DP1 [73] | Eosinophils [74], Basophils [80], Platelets [73], Nervous System [84]                      | Lipid droplet biogenesis [74], Inhibits migration and degranulation [80], Platelet aggregation [85,86], Cognitive function, [84], sensory nerve activation [87] |
| **PGE<sub>2</sub>** | Endothelial cells, monocytes, macrophages, osteoblasts, and fibroblasts [14], DCs [88,89] | EP1, EP2, EP3 and EP4 [90–94] | Eosinophils [95,96], T lymphocytes [88], Keratinocytes [97,98], Airway epithelial cells [99,100], ILC2s [92,101], Mast cells [102,103], DCs [89,104] | Abrogation of eosinophil migration and accumulation and release of ROS [37,95,96], Suppression of differentiation of Th2 cells [88], Suppression of chemokine production [98], Suppression of release of chemokines [99] and mucin production [100], Decreased ILC2 proliferation and Type 2 cytokine production [92,101], Inhibits degranulation [102,103], Induces priming of Th2 cells [89], Suppression of DC proinflammatory effects [104] |
|           |                                                                                | IP [105] | Th2 cells [106,107], T regulatory cells [107], Platelets [108], Neuronal cells [108], Endothelial cells [108], DCs [109,110], ILC2s [111], Eosinophils [112] | Suppression via IL-10 production [106], Suppresses Type 2 cytokine production, [113–115], Inhibits CD4 T cell proliferation [113], Influences recruitment of Th2 cells [107], Induces T regulatory cell differentiation [116], Antithrombotic role [117], Involved in nociceptive response [117], Regulate vascular permeability/vasodilation [108,117], Induction of production of IL-10 [116,118], Regulation of chemokine production [109], Regulation of migration [109,110], Regulates release of inflammatory mediators [110], Inhibits ILC2 proliferation [111], Inhibits ILC2 Type 2 cytokine production [111], Inhibits recruitment and migration [112,119], Prothrombosis [26,120,123], Proinflammatory role [121] |
| **PGI<sub>2</sub>** | Fibroblasts, follicular DCs, endothelial cells, smooth muscle cells and thymic nurse cells [105] | IP [105] | Th2 cells [106,107], T regulatory cells [107], Platelets [108], Neuronal cells [108], Endothelial cells [108], DCs [109,110], ILC2s [111], Eosinophils [112] | Suppression via IL-10 production [106], Suppresses Type 2 cytokine production, [113–115], Inhibits CD4 T cell proliferation [113], Influences recruitment of Th2 cells [107], Induces T regulatory cell differentiation [116], Antithrombotic role [117], Involved in nociceptive response [117], Regulate vascular permeability/vasodilation [108,117], Induction of production of IL-10 [116,118], Regulation of chemokine production [109], Regulation of migration [109,110], Regulates release of inflammatory mediators [110], Inhibits ILC2 proliferation [111], Inhibits ILC2 Type 2 cytokine production [111], Inhibits recruitment and migration [112,119], Prothrombosis [26,120,123], Proinflammatory role [121] |
| **Thromboxane** | Activated platelets [120], DCs [121], Macrophages [122] | TP [121] (mice), TPs, TP<sub>β</sub> [26] (human) | Platelets [26], T lymphocytes [121] | Prothrombosis [26,120,123], Proinflammatory role [121] |

Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2), dendritic cells (DCs), prostaglandin E<sub>2</sub> receptor (EP), group 2 innate lymphoid cells (ILC2s), PGI<sub>2</sub> receptor (IP), Th2 (T helper type 2), thromboxane receptor (TP).
Figure 1. Prostaglandin synthesis cascade. Phospholipase A2 (PLA2) releases free fatty acids, including arachidonic acid (AA), from membrane phospholipid stores. From AA, lipoxygenase enzymes synthesize leukotrienes and cytochrome P450 epoxygenases (CYP) synthesize epoxyeicosatrienoic acids. For prostanoid production, AA is metabolized through the cyclooxygenase (COX) pathway by COX1 and COX2, which catalyze the bioxygensation and cyclization of released AA to form PGG2 as well as the peroxidation of PGG2 to PGH2. PGH2 is then converted by prostaglandin D synthase (PGDS), prostaglandin E synthase (PGES), prostaglandin F synthase (PGFS), prostaglandin I2 synthase (PGIS) and thromboxane A synthase (TXAS) to synthesize PGD2, PGE2, PGF2α, PGI2, and thromboxane A2 (TXA2), respectively.

and other prostanoids were released in the acute phase of *Nippostrongylus brasiliensis*-induced Type 2 inflammation than during chronic house dust mite (HDM) exposure in the lungs in mice [67]. Increased PGD2 production in helminth infection compared to allergic inflammation was attributed to context-specific lung macrophage reprogramming, though the time point in the inflammatory arc that was assessed in these two models [67] and the potential for helminths to be endogenous sources of PGD2 and other prostanoids [130] may also have contributed.

The increase in PGD2 levels during Type 2 inflammation has largely been associated with proinflammatory roles for this pathway via effects on immune cells that express CRTH2 [17,78,131,132] (Fig. 2). PGD2 binds to CRTH2 on eosinophils, ILC2s, basophils, and Th2 cells to induce cellular migration and cytokine production [77,80, 78, 81,131,133]. We have the most understanding about the effects of PGD2 and CRTH2 on murine and human cells in vitro and in vivo in mouse models of helminth- and allergen-elicited lung inflammation and in
Figure 2. Role of PGD2 and PGE2 in regulating Type 2 inflammation at an epithelial barrier. Schematic diagram depicting the role of PGD2 (pleiotropic) and PGE2 (mostly anti-inflammatory) at an example epithelial barrier, the small intestine. PGD2 acts through its receptor CRTH2 on ILC2s, basophils, eosinophils, and Th2 lymphocytes to induce cytokine production and migration of immune cells during helminth- and allergen-induced Type 2 inflammation. It also acts on CRTH2-expressing intestinal epithelial cells to counteract the Type 2 inflammatory program. PGE2 acts through its receptors EP2 and EP4 on eosinophils, mast cells, Th2 cells, ILC2s, epithelial cells, and DCs. PGE2 can inhibit eosinophil chemotaxis and degranulation and mast cell degranulation, regulate T-cell activation, regulate ILC2 proliferation and chemotaxis, and induce an immunoregulatory phenotype in DCs. Some studies have also shown the PGE2 acts on macrophages and DCs and to support the ability of these cells to prime Th2 cells, and thus, the effects of PGE2 on Th2 responses can be direct or indirect and are context-dependent. PGE2 can also increase epithelial permeability and secretory function.

allergic lung inflammation in humans. In the lungs, the PGD2-CRTH2 pathway promotes Type 2 cytokine production and tissue migration or accumulation of ILC2s, during allergic inflammation and in response to helminth migration through the lung tissue in murine models [17,78,131]. Some data in murine models of inflammation show that this pathway might have similar proinflammatory roles in other tissue sites like the skin, for example, during allergic skin inflammation [134,135] and in the gut dur-
Prostaglandins are involved in different phases of inflammation during helminth infection. Schematic diagram showing the role different prostaglandins play during (A) initiation, (B) activation, (C) effector, and (D) regulatory phases of inflammation. Parasitic helminths and their associated excretory/secretory factors elicit the production of proinflammatory prostanooids like PGD\(_2\) from macrophages (Macs), mast cells, epithelial cells, and other cell types and TXA\(_2\) from activated platelets. The effects of TXA\(_2\) are currently unclear. PGD\(_2\) may also be synthesized by parasites. PGD\(_2\) produced by the host and the parasite is critical during the initiation phase of the inflammatory process (A), activating key innate immune cell types that then release proinflammatory cytokines, chemokines, and in some cases more proinflammatory prostanooids (B). These mediators recruit and activate effector immune cells and promote the production and release of Type 2 cytokines, including IL-13 that acts on the epithelium to promote inflammatory changes (C). Bioactive mediators such as PGE\(_2\) and PGI\(_2\) are immunoregulatory and can restrain or resolve the Type 2 response, though PGE\(_2\) may act on DCs to support their ability to prime Th2 cells (not depicted). Regulatory prostanooids are released in response to helminths and their products, and helminths have been shown to synthesize and release PGE\(_2\). Stromal cell-derived PGI\(_2\) dampens Th2 and ILC2 activation. PGE\(_2\) derived from alternatively activated macrophages (AA Macs) and possibly parasites also restrain Th2, ILC2, and eosinophil responses and may also act on epithelial cells to promote wound healing. PGD\(_2\) can also play a regulatory role depending on the context, acting on small intestine epithelial cells to negatively regulate the epithelial response to helminth infection (D).

Figure 3. Prostaglandins are involved in different phases of inflammation during helminth infection. Schematic diagram showing the role different prostaglandins play during (A) initiation, (B) activation, (C) effector, and (D) regulatory phases of inflammation. Parasitic helminths and their associated excretory/secretory factors elicit the production of proinflammatory prostanooids like PGD\(_2\) from macrophages (Macs), mast cells, epithelial cells, and other cell types and TXA\(_2\) from activated platelets. The effects of TXA\(_2\) are currently unclear. PGD\(_2\) may also be synthesized by parasites. PGD\(_2\) produced by the host and the parasite is critical during the initiation phase of the inflammatory process (A), activating key innate immune cell types that then release proinflammatory cytokines, chemokines, and in some cases more proinflammatory prostanooids (B). These mediators recruit and activate effector immune cells and promote the production and release of Type 2 cytokines, including IL-13 that acts on the epithelium to promote inflammatory changes (C). Bioactive mediators such as PGE\(_2\) and PGI\(_2\) are immunoregulatory and can restrain or resolve the Type 2 response, though PGE\(_2\) may act on DCs to support their ability to prime Th2 cells (not depicted). Regulatory prostanooids are released in response to helminths and their products, and helminths have been shown to synthesize and release PGE\(_2\). Stromal cell-derived PGI\(_2\) dampens Th2 and ILC2 activation. PGE\(_2\) derived from alternatively activated macrophages (AA Macs) and possibly parasites also restrain Th2, ILC2, and eosinophil responses and may also act on epithelial cells to promote wound healing. PGD\(_2\) can also play a regulatory role depending on the context, acting on small intestine epithelial cells to negatively regulate the epithelial response to helminth infection (D).

Prostaglandin E\(_2\)

PGE\(_2\) is another product of the prostaglandin synthesis pathway, synthesized by the conversion of the direct precursor PGH\(_2\) to PGE\(_2\) by PGES. PGE\(_2\) is produced by various cell types including but not limited to endothelial cells, monocytes/macrophages, osteoblasts, and fibroblasts [14]. This lipid mediator exerts its function by binding to the PGE\(_2\) receptors EP1, EP2, EP3, or EP4, which are expressed by a wide variety of cell types. The role...
of PGE₂ in various contexts, such as during autoimmunity, cancer, and chronic inflammation, has been well documented, with PGE₂ playing both pro- and/or anti-inflammatory roles depending on receptor usage, disease context, and timing of inflammation [56,90–94] (Table 1).

During Type 2 inflammation, the most well-documented role for PGE₂ is anti-inflammatory [92,98,99] (Fig. 2). The study of various models of Type 2 inflammation either in the skin [98,139] or in the lungs [37,99,101,140–145] has demonstrated this effect. For example, Zhou et al. showed that PGE₂ suppressed lung pathology in an IL-33-elicited allergic inflammation model in mice, via binding to the receptor EP4 to induce its response, as EP4-deficient mice displayed exacerbated inflammation in the Alternaria-induced asthma model. EP engagement suppressed expression of the IL-33 receptor, ST2, as well as Gata3 transcription, both important factors for ILC2 activation and Type 2 inflammatory responses [101]. A suppressive role for PGE₂ was previously reported in an ovalbumin-elicited model of allergic inflammation as well [99].

In the context of helminth infection, some studies have also demonstrated increased production of PGE₂ and have proposed similar immunoregulatory functions. Brattig et al. showed that PGE₂ production can be induced in human macrophages following infection with *Onchocerca volvulus* [146]. While some studies have suggested that PGE₂ has no role in clearance of *N. brasiliensis* from the intestine of mice [147], de los Reyes Jiménez et al. recently showed that production of PGE₂ stimulated by helminth-derived larval products can lead to suppression of eosinophilic airway inflammation and lung pathology in an HDM-induced airway model of Type 2 inflammation [37]. In addition, some other studies have shown that PGE₂ acts through its receptors EP2 and EP4 to regulate proliferation and Type 2 cytokine production from activated ILC2s [92], the migration and release of inflammatory mediators in eosinophils [95,96], degranulation of mast cells [102,103], and immunomodulatory effects in DCs [104]. All of these findings strongly suggest an anti-inflammatory or regulatory role for PGE₂ during Type 2 inflammation (Fig. 3).

Of note, a few studies suggest that PGE₂ can also have a proinflammatory role in the regulation of Type 2 inflammation or can alter the balance of Type 1 versus Type 2 inflammation to allow for the emergence of a Type 2 response [89,140,148]. For example, Kaisar and others showed that PGE₂, a component of *Schistosoma mansoni* soluble egg antigen, could act on DCs to induce expression of OX40 ligand. This effect influenced the dynamics of production of Type 1 and Type 2 cytokines from T cells that consequently allowed for Th2 responses [89]. PGE₂ may also play a key role in skewing toward a Th2 response via suppression of a Th1 response. This can occur through regulation of cytokine production by human DCs [149] and regulation of macrophage responses in genetically Th2-prone inbred mouse strains [150]. Furthermore, Church et al. demonstrated that mice lacking the microsomal PGE₂ synthase-1 (mPGES1), which is important in production of PGE₂, had decreased immune cell infiltration and Type 2 cytokine production in an ovalbumin-induced model of Type 2 inflammation [140]. It is important to keep in mind that in this study, the inflammation observed in the absence of PGE₂ could be due to the loss of direct effects of PGE₂ or to shunting of the prostaglandin synthesis pathway into overproduction of more proinflammatory prostaglandins in the absence of the ability to make PGE₂. Finally, Shea-Donohue and colleagues showed that PGE₂ stimulation of intestinal sections mounted in an Ussing chamber increased mucosal permeability, reduced sodium-linked glucose absorption, and increased secretory responses. These changes were only seen in intestinal sections harvested from mice during secondary but not primary *Heligmosomoides polygyrus* infection [151], demonstrating that the proinflammatory role for PGE₂ came into play after the induction of an adaptive Th2 response and in the epithelial effector phase of Type 2 inflammation, as previously reported [140]. Taken together, these studies suggest that the pro- versus anti-inflammatory effects of PGE₂, acting through its various receptors, might be regulated by the timing and stage of inflammation, at least in the context of helminth infection [104]. Therefore, newly developed mouse models [152] that allow for timed deletion of various genes that govern PGE₂ synthesis and function can be used to carefully explore how PGE₂ regulates Type 2 responses at various stages of inflammation.

**Prostaglandin I₂**

PGI₂ or prostacyclin is another end product of the prostaglandin biosynthesis pathway, synthesized through the sequential metabolism of AAs by the COX enzymes and PGIS. Several cell types, including fibroblasts, DCs, endothelial cells, smooth muscle cells, and thymic nurse cells, have been shown to express enzymes that produce this lipid mediator [105,153–155]. Prostacyclin binds to the G-coupled protein receptor IP to elicit its effect [105]. This receptor is expressed in a variety of cells and tissues including but not limited to neuronal cells, endothelial cells, smooth muscle cells and platelets [108]. PGI₂ acts on platelets to inhibit platelet aggregation, on blood vessels to regulate vascular permeability and on neuronal cells to regulate pain and nociceptive responses [117,156]. Immune cells, such as neutrophils, DCs, eosinophils, and Th2 lymphocytes cells, also express IP [105,106,118] (Table 1).

PGI₂ production is elicited in various Type 2 inflammatory contexts and has been implicated mostly as an immunomodulatory factor, acting at the resolution phase of Type 2 inflammation [106,110,111,118,157–161] (Fig. 3). For example, during allergen-induced Type 2 inflammation in the lungs of mice, PGI₂ binds to IP to suppress Type 2 inflammation through induction of production and release of IL-10 from Th2 cells [106] and DCs [116,118]. In addition, PGI₂ has been shown to suppress production and release of Type 2 cytokines [110,158,159] from ILC2s [159], Th2 lymphocytes [113,114,157], and DCs [110]; potentiate differentiation of Tregs [116]; and regulate production and release of IL-2, a T-cell prosurvival factor [159]. Furthermore, this lipid mediator can influence the accumulation, recruitment, and migration of Type 2 immune cells including ILC2s.
[111], eosinophils [112,119], Th2 lymphocytes [107], and DCs [109,110]. While PGI₂ seems to have a clear regulatory role in the lungs in murine models of allergic inflammation, its role during helminth infection remains less clear. PGI₂ production is dependent on Type 2 cytokines during helminth infection [162], but its effects in this context remain poorly understood.

**Thromboxane A₂**

TXA₂ is another product of the prostaglandin synthesis pathway produced following direct metabolism of PGH₂ to TXA₂ by TXAS [122]. This prostanoid has a less defined role in the modulation of Type 2 inflammation, possibly due to its short half-life. Most studies of this lipid provide evidence for prothrombotic properties following production by activated platelets, with platelets expressing both TXA₂ and thromboxane receptor (TP) [120,122]. However, DC [121] and macrophage [123] production of TXA₂ can also regulate immune responses in the steady state and in vitro coculture models [121] (Table 1).

TXA₂ appears to be largely proinflammatory, outside of its platelet effects. Mice deficient in TP had attenuated immune responses following inflammation in a model of tissue injury [163]. Similarly, Yamasaki et al. showed that treatment with either seratrodast, a TXA₂ antagonist, or ozagret, a TXAS inhibitor, significantly reduced vascular permeability, swelling, and intranasal pressure in a guinea pig model of allergic rhinitis [164]. The TP antagonist BAYu 3405 could also alleviate allergen-induced nasal symptoms, total airway resistance, and eosinophil infiltration in guinea pigs [165]. Furthermore, the TXA₂-TP pathway interacts with other prostanoids, such as PGE₂, to control inflammation. For example, a study by Liu et al. showed that during HDM-elicited allergic airway inflammation, exaggerated pulmonary eosinophilia and vascular remodeling seen in PGE₂-deficient mice could be abrogated by deletion of TP [166]. These data suggest that PGE₂ effects might dampen Type 2 immune responses by repressing the inflammatory TXA₂-TP effector circuit [166].

However, much less is known about the role of TXA₂ during helminth infection (Fig. 3). Humans infected with *Dirofilaria immitis* who had pulmonary dirofilariasis had significantly higher TXA₂ levels in the serum than healthy control individuals, although it was not clear whether this was elicited by the helminth parasite or secondary infection with the symbiotic Wolbachia bacteria, which is present in most filarial parasites and is associated with septic shock [167]. Therefore, further studies are necessary to investigate the role of TXA₂ during helminth-induced Type 2 inflammation in various tissue sites.

**Prostaglandin F₂α**

PGF₂α is the last in this family of prostaglandins. It is synthesized from PGH₂ via PGFS [22,168] and binds to a G-coupled protein receptor, FP [22]. The FP receptor is one of the least selective of the prostanoid receptors, ligating PGF₂α and other prostaglandins in the series such as PGD₂ and PGE₂ [169]. PGF₂α is produced by various cells and tissues, including adipocytes, renal tissue, and tissues of the reproductive system, and regulates various physiologic processes [22,37,170] (Table 1). Little is known about the role of this prostanoid and its receptor in the regulation of Type 2 inflammation, in mice or humans. A few older studies have suggested that PGF₂α is important in regulation of airway conductance [171,172] and also plays a role in regulation of various acute and chronic models of inflammation, but there has been little evidence of a direct influence of this pathway on immune cells [22]. Also, more recent studies have shown that PGF₂α was significantly increased in the BALF of mice following infection with *N. brasilensis* at day 5 post-infection but not following exposure to HDM allergen [67]. Furthermore, helminth excretory secretory products (HES) from *H. polygrus* larvae induced PGF₂α production from human monocyte-derived macrophages [37]. Together, these data suggest that PGF₂α and FP might play a role during Type 2 inflammation, but the specific functions of the PGF₂α-FP pathway during allergy and helminth infection remain to be fully defined.

**Host- and parasite-derived prostaglandin networks regulate Type 2 inflammation**

Due to their pleiotropic roles in tissues, it is perhaps not surprising that prostaglandins regulate complex networks of responses. As such, these oxylipids are uniquely placed to serve critical functions in balancing immunological interactions. These include but are not limited to interactions between host and pathogen during helminth infection, or known interactions and associations between Type 2 inflammatory responses during allergic disease and helminth infection [173].

In the context of parasite infection, both host- and parasite-derived prostaglandins dictate the outcomes of the host-pathogen interaction, including persistence versus expulsion of the parasite and the extent of collateral damage to the host. Various protozoan parasites, like *Acanthamoeba, Entamoeba histolytica, Plasmodium, Toxoplasma gondii*, and Trypanosomes, among others, can produce prostaglandins (reviewed here [15,23,174]). Other metazoan and parasitic helminthes, like Schistosomes and *Onchocerca* spp., also produce prostaglandins [130,175–179] that have host immunomodulatory roles. For example, *S. mansoni*, a parasitic worm that chronically infects humans, can produce lipid mediators including prostaglandins at various stages of its lifecycle [180–182]. Schistosomes produce PGD₂ that mediates proinflammatory effects in the host, including activation of eosinophils [74], as well as immunomodulatory PGE₂ that can induce production of IL-10 that promotes migration and survival of the parasite [89,176,177,180]. In addition, other helminth parasites, such as microfilaria of *B. malayi*, have also been shown to produce PGD₂, PGF₂α, 6-keto-PGF₁α, PGF₂α, and TXB₂ [183,184]. These lipids play immunomodulatory roles in the host and influence critical physiological tissue responses to injury, preventing platelet
aggregation around the parasites as they grow in blood vessels [184,185]. Furthermore, other worms, like Trichuris suis, a whipworm, produces PGE2 that can directly suppress production of cytokines in LPS-stimulated DCs [104] (Table 2).

In some cases, the pathogen-host crosstalk via lipid mediators is indirect, with parasite products directly eliciting host prostaglandin production. HES from parasites, such as H. polygyrus and S. mansoni, can act on host immune cells to induce production of host-derived lipid mediators [37,89]. As described above, soluble egg antigen from S. mansoni can trigger the production and release of PGE2 from DCs that subsequently license Th2 cells [89]. Similarly, larval products from H. polygyrus, dependent on Hpb glutamate dehydrogenase, can condition macrophages and granulocytes to produce PGE2 that has immunomodulatory roles during chronic Type 2 immune responses [37]. This study has clear implications for our understanding of the inverse relationship between rates of helminth infection and rates of allergic disease across the globe [173]. While it has long been observed that helminth infection may confer protective effects against the development of allergic disease, the molecular mechanisms that underlie this phenomenon are not fully understood. The demonstration that PGE2 stimulated by helminth-derived larval products can lead to suppression of HDM-induced Type 2 inflammation provides one such mechanism [37]. Another study showed that infection of rats with Angiostrongylus costaricensis elicited PGE2 and lipoxin production that enhanced the resolution of allergic edema in the pleural cavity after allergen challenge [185]. While much remains to be discovered related to how prostaglandins might regulate the interplay between allergic and antihelminth responses, it appears likely that prostanoids are key factors in modulating this relationship.

Thus, either direct prostaglandin production by parasites or parasite product-elicited host prostaglandin production is important for mediating host-helminth interactions as well as immune responses to other stimuli like allergens. This crosstalk may govern the establishment and survival of the parasite, and the initiation, activation, and/or immunomodulation of host immune responses (Fig. 3). Parasite-derived prostanoids can be considered virulence factors that promote chronic infection and/or disease pathogenesis, modulating immune responses in the host to improve the survival of the parasite. However, these could also be considered beneficial products that prevent or limit inappropriate inflammation in response to allergens. These parasite-derived prostanoids may promote tissue repair, supporting epithelial cell proliferation and migration, ECM deposition, tissue remodeling and regeneration of endothelial cells. Thus, parasite-derived prostanoids may be critical for dictating host responses to allergens and helminth infection [21]. Clearly, disentangling the effects of parasite- versus host-derived prostaglandins during infection, and effects on allergic disease, will be complex. Studies that address this important question will require the use of new technologies for genetic manipulation of helminth parasites, such

### Table 2. Parasite-derived prostaglandins and their effects on the host

| Metazoan parasite | Prostaglandin | Role and function | References |
|-------------------|---------------|-------------------|------------|
| Schistosoma mansoni | PGD2 [180] | Impedes TNFα-triggered migration of epidermal Langerhans cells | [130] [74,175] |
|                    | PGE2 [180] | Eosinophil activation and lipid biogenesis | [176,177] [89,180] |
| Onchocerca volvulus | PGD2, PGE2 | Unknown | [178] |
| Brugia malayi | PGE2 [183,185] | Immunomodulation? | [179] |
| Wuchereria bancrofti | PGE2 [185] | Immunomodulation? | [185] |
| Trichuris suis | PGE2 [104] | Modulates proinflammatory DC responses | [104] |
| Diphyllolothrium dendriticum | PGE2 [186] | Immunomodulation? | [186] |
| Fasciola hepatica | TXB2, PGI2, PGE2 [187] | Immunomodulation? | [187] |
as transgenic parasite models, CRISPR-Cas techniques [188,189], and RNA interference [190], coupled with genetic manipulations of host prostaglandin signaling and well-defined models of parasite infection and allergic disease.

Prostaglandin biology in human disease

The synthesis cascades that result in prostaglandin production offer multiple opportunities for therapeutic intervention in human disease. While many of the studies we have discussed thus far involved the use of mouse models, drugs and inhibitors that target specific prostaglandin synthesis pathways or block the different receptors for the individual prostaglandins are being tested for efficacy in treating human diseases. To date, the various complexities associated with interfering in the synthesis of prostaglandins (i.e. the possibility of shuttling into different pathways and the pleiotropic effects of individual prostaglandins) have made the use of receptor inhibitors and agonists more attractive. While prostaglandin-targeting drugs are used in a number of contexts, they have been of particular interest in treating signs and symptoms of allergic inflammation in humans.

PGD$_2$, one of the key prostaglandin mediators produced during Type 2 inflammation, can have both pro- and anti-inflammatory roles during Type 2 inflammation depending on the context and tissue [70,131] or receptor affinity for either CRTH2 or DP1 [191]. Therefore, specific drugs that target these receptors have been used to modulate these responses in human disease, extensively discussed here [75,192], and with selected highlights in Table 3. The DP1 antagonists BW A868C and S-5751 have been used in the treatment of allergic disease to alleviate allergen-induced Type 2-associated symptoms [193]. Also, CRTH2 antagonists like Ramatroban (BAY U3405) that antagonize both CRTH2 and the TXA$_2$ receptor have been used for the treatment of allergic rhinitis [194–196], blocking chemotaxis of Type 2 immune cells like eosinophils, basophils, Th2 lymphocytes, and ILC2s into inflamed tissues [196–198]. Similarly, OC000459, a CRTH2 competitive antagonist, was shown to have potential for use in cases of airway inflammation, where it can inhibit airway and blood eosinophilia when delivered orally to rats and guinea pigs [199]. Drugs like Vidupiprant (AMG-853, Amgen) that target and block both the DP1 and DP2 receptors [200] appear to have been less successful in the treatment of allergic inflammation [201]; thus, more attention has been paid to CRTH2 inhibition in treating human allergic disease [75,202,203]. Key and foremost among these CRTH2 antagonists [75] is Fevipiprant, an oral, nonsteroidal, highly selective, safe, reversible antagonist of the DP2 receptor that inhibits the binding of all ligands [204]. While Fevipiprant showed great promise in the amelioration of symptoms of eosinophilic airway inflammation in phase II clinical trials [192,203], recent larger scale phase III clinical trials report a marginal improvement in disease activity with the use of this drug over placebo for the treatment of severe airway Type 2 inflammation [202]. Thus, it remains to be seen whether Fevipiprant and other CRTH2 inhibitors are useful in defined endotypes and phenotypes of allergic inflammation. The pleiotropic effects of PGD$_2$ and CRTH2 on different cell types (epithelial vs. immune) [70] could influence therapeutic efficacy of these drugs, especially considering the importance of the epithelial-immune cell crosstalk during Type 2 inflammation.

Table 3. Selected Drugs for Potential Use during Type 2 inflammation in Humans

| Drug name               | Target          | Model of study | Disease                                       | References |
|-------------------------|-----------------|----------------|-----------------------------------------------|------------|
| AM156                   | CRTH2           | Mice           | Allergic rhinitis, asthma                     | [205]      |
| BW A868C                | DP1             | Guinea pigs    | Allergic rhinitis, allergic conjunctivitis, asthma | [193]      |
| S-5751                  | DP1             | Guinea pigs    | Allergic rhinitis, allergic conjunctivitis, asthma | [193,206]  |
|                         |                 | Sheep          | Asthma                                        | [207]      |
| Ramatroban (BAY U3405)  | CRTH2           | Mice           | Allergic rhinitis                            | [209]      |
|                         |                 | Humans         | Allergic rhinitis                            | [195]      |
| OC000459                | CRTH2           | Guinea pigs    | Airway eosinophilia                           | [199]      |
|                         |                 | Mice           | Airway inflammation                          | [209]      |
|                         |                 | Humans         | Allergic rhinitis, allergic conjunctivitis    | [210]      |
|                         |                 | Humans         | Asthma                                        | [211–213]  |
| Vidupiprant (AMG-853, Amgen) | DP1 and CRTH2 | Human          | Eosinophilic airway inflammation             | [200,201]  |
| Fevipiprant (QAW039)    | CRTH2           | Humans         | Asthma                                        | [214]      |

Prostaglandin biology in human disease

The synthesis cascades that result in prostaglandin production offer multiple opportunities for therapeutic intervention in human disease. While many of the studies we have discussed thus far involved the use of mouse models, drugs and inhibitors that target specific prostaglandin synthesis pathways or block the different receptors for the individual prostaglandins are being tested for efficacy in treating human diseases. To date, the various complexities associated with interfering in the synthesis of prostaglandins (i.e. the possibility of shuttling into different pathways and the pleiotropic effects of individual prostaglandins) have made the use of receptor inhibitors and agonists more attractive. While prostaglandin-targeting drugs are used in a number of contexts, they have been of particular interest in treating signs and symptoms of allergic inflammation in humans.

PGD$_2$, one of the key prostaglandin mediators produced during Type 2 inflammation, can have both pro- and anti-inflammatory roles during Type 2 inflammation depending on the context and tissue [70,131] or receptor affinity for either CRTH2 or DP1 [191]. Therefore, specific drugs that target these receptors have been used to modulate these responses in human disease, extensively discussed here [75,192], and with selected highlights in Table 3. The DP1 antagonists BW A868C and S-5751 have been used in the treatment of allergic disease to alleviate allergen-induced Type 2-associated symptoms [193]. Also, CRTH2 antagonists like Ramatroban (BAY U3405) that antagonize both CRTH2 and the TXA$_2$ receptor have been used for the treatment of allergic rhinitis [194–196], blocking chemotaxis of Type 2 immune cells like eosinophils, basophils, Th2 lymphocytes, and ILC2s into inflamed tissues [196–198]. Similarly, OC000459, a CRTH2 competitive antagonist, was shown to have potential for use in cases of airway inflammation, where it can inhibit airway and blood eosinophilia when delivered orally to rats and guinea pigs [199]. Drugs like Vidupiprant (AMG-853, Amgen) that target and block both the DP1 and DP2 receptors [200] appear to have been less successful in the treatment of allergic inflammation [201]; thus, more attention has been paid to CRTH2 inhibition in treating human allergic disease [75,202,203]. Key and foremost among these CRTH2 antagonists [75] is Fevipiprant, an oral, nonsteroidal, highly selective, safe, reversible antagonist of the DP2 receptor that inhibits the binding of all ligands [204]. While Fevipiprant showed great promise in the amelioration of symptoms of eosinophilic airway inflammation in phase II clinical trials [192,203], recent larger scale phase III clinical trials report a marginal improvement in disease activity with the use of this drug over placebo for the treatment of severe airway Type 2 inflammation [202]. Thus, it remains to be seen whether Fevipiprant and other CRTH2 inhibitors are useful in defined endotypes and phenotypes of allergic inflammation. The pleiotropic effects of PGD$_2$ and CRTH2 on different cell types (epithelial vs. immune) [70] could influence therapeutic efficacy of these drugs, especially considering the importance of the epithelial-immune cell crosstalk during Type 2 inflammation.
Conclusions and future directions

Recent work has expanded upon classical literature that demonstrates key roles for prostaglandins in regulating Type 2 inflammation in allergy and helminth infection [37, 67, 89, 92, 104, 131, 145]. The development of specific and powerful prostaglandin receptor inhibitors and agonists has allowed for more granular study of the effects of specific prostaglandins and their receptors during helminth infection, allergic disease, and fibrosis [26, 101, 145]. Complementarily, new mouse models that allow for the genetic deletion of prostaglandin synthesis ability or specific prostaglandin receptors have been used to reveal the complex biology that prostaglandins control in tissues [22, 145, 152]. Together, these tools are being leveraged to disentangle the pleiotropic effects of prostaglandins during the steady state and Type 2 inflammation.

Despite these advances, much remains to be explored in the field of prostaglandin biology during Type 2 inflammation. In particular, cell lineage-specific deletion in mice of various components of different prostaglandin pathways is not possible in all cases. Mice that allow for such lineage-specific and inducible deletion of prostaglandin synthases and receptors will be required for building a greater understanding of the effects of individual prostaglandins in various disease states in time and space. Also, currently, in vivo visualization of prostaglandin production in mice is not possible, and tools that make that feasible could revolutionize our understanding of prostaglandin regulation of inflammation in tissues. Such studies in mice will be needed to inform further work in humans that builds understanding of human prostaglandin biology and uses this knowledge to treat diseases that involve a pathologic Type 2 inflammatory component. Of particular interest would be to better understand how host- and parasite-derived prostaglandins modulate host-pathogen interactions and shape host immune responses to impact on the development or progression of allergic responses. Defining the networks of prostaglandins that regulate Type 2 inflammation using mouse models and translational work in human tissue culture has the potential to reveal rich opportunities for therapeutic intervention in Type 2 inflammation-driven allergic disease and fibrosis in humans.

Acknowledgments: We acknowledge the valuable work of all investigators that we could not cite due to space limitations. Some of the figures were created using Biorender.com and from the Servier Medical Art’s image collection. This work was supported by the National Institutes of Health/National Institute of Allergy and Infectious Diseases (K22 AI116729 and R01 AI130379 to E.D.T.W.). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the views of the National Institutes of Health. Authors thank members of the Tait Wojno lab for help in reading the manuscript.

Conflict of interest: The authors declare no commercial or financial conflict of interest.

References

1 Wynn, T. A., Type 2 cytokines: mechanisms and therapeutic strategies. Nat. Rev. Immunol. 2015. 15: 271–282.
2 Gieseck, R. L., Wilson, M. S. and Wynn, T. A., Type 2 immunity in tissue repair and fibrosis. Nat. Rev. Immunol. 2018. 18: 62–76.
3 Colley, D. G., Bustinduy, A. L., Secor, W. E. and King, C. H., Human schistosomiasis. Lancet North Am. Ed. 2014. 383: 2253–2264.
4 Salgame, P., Yap, G. S. and Gause, W. C., Effect of helminth-induced immunity on infections with microbial pathogens. Nat. Immunol. 2013. 14: 1118–1126.
5 Potian, J. A., Rafi, W., Bhatt, K., McBride, A., Gause, W. C. and Salgame, P., Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway. J. Exp. Med. 2011. 208: 1863–1874.
6 Molofsky, A. B., Nussbaum, J. C., Liang, H.-E., Van Dyken, S. J., Cheng, L. E., Mohapatra, A., Chawla, A. et al., Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J. Exp. Med. 2013. 210: 535–549.
7 von Moltke, J. and Locksley, R. M., I-L-C-2 it: type 2 immunity and group 2 innate lymphoid cells in homeostasis. Curr. Opin. Immunol. 2014. 31: 58–65.
PGD2 and 15-deoxyeicosatetraenoic acid (15dEET) are key mediators of immune and inflammatory responses during helminth infections. PGD2 and 15dEET are produced by various cell types, including mast cells, macrophages, and dendritic cells, and act as autocrine and paracrine mediators to regulate immune responses. These lipids are involved in the modulation of innate immune responses and the induction of type 2 immunity.

Recent studies have shown that PGD2 and 15dEET can promote the differentiation of type 2 innate lymphoid cells (ILC2s), which are key players in the induction of type 2 immunity. ILC2s are induced by helminth infection and secrete interleukin-5 (IL-5) and interleukin-13 (IL-13), which are crucial for the induction of type 2 immunity.

PGD2 and 15dEET can also promote the differentiation of regulatory T cells (Tregs), which are important for the suppression of autoimmune responses. These lipids can act as chemoattractants for Tregs and promote their survival and function.

In addition, PGD2 and 15dEET can modulate the function of other immune cells, such as dendritic cells and macrophages, which are crucial for the induction of type 2 immunity. These lipids can promote the differentiation of dendritic cells into type 2-polarized cells and enhance the production of type 2 cytokines by macrophages.

Overall, PGD2 and 15dEET are key mediators of immune and inflammatory responses during helminth infections. These lipids play a crucial role in the induction of type 2 immunity and the regulation of immune responses. Further research is needed to fully understand the role of PGD2 and 15dEET in the modulation of immune responses during helminth infections.
Hamberg, M. and Samuelsen, B., On the mechanism of the biosynthesis of prostaglandins E1 and F2. J. Biol. Chem. 1967. 242: 5336-5343.

Hamberg, M., Svensson, J. and Samuelsen, B., Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. U.S.A. 1975. 72: 2994–2998.

Dubois, R. N., Kanikarla-Marie, P., Suzuki-Yamamoto, T., Zeldin, D. C., Jakobsson, P.-J., Urade, Y., Kalinski, P., De Putte, L. B., Aritake, K., Udare, Y. and Yokozeki, H., Proc. Natl. Acad. Sci. U.S.A. 2000. 97: 1063-1073.

Urade, Y. and Hayashi, O., Prostaglandin D synthase: structure and function. Virum. Norm. 2000. 58: 89-120.

Jakobsen, P.-J., Thorén, S., Morgenstern, R. and Samuelsen, B., Identification of human prostaglandin F synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. 1999. 96: 7220–7225.

Suzuki-Yamamoto, T., Nishizawa, M., Fukui, M., Okuda-Ashitaka, E., Nakajima, T., Ito, S. and Watanabe, K., cDNA cloning, expression and characterization of human prostaglandin F synthase111The amino acid sequence of human PGFS and the amplified genomic DNA with PGFS-F4 and B5 were registered in the DDBJ under accession no. AB018580 and no. AB028065, respectively. FEBS Lett. 1999. 462: 335-340.

Watanabe, K., Prostaglandin F synthase. Prostaglandins Other Lipid Mediat. 2002. 68-69: 401-407.

Burgess, J. R., Yang, H., Chang, M., Rao, M. K., Tu, C. P.-D. and Reddy, C., Enzymatic transformation of PGH2 to PGF2α catalyzed by glutathione-S-transferases. Biochem. Biophys. Res. Commun. 1987. 142: 441-447.

Needleman, P., Moncada, S., Bunting, S., Vane, J. R., Hamberg, M. and Samuelsen, B., Identification of an enzyme in platelet micromes which generates thromboxane A2 from prostaglandin endoperoxides. Nature 1976. 261: 558-560.

Polese, B., Thurairajah, B., Zhang, H., S00, C. L., McMahon, C. A. and Fontes, G., Hussain, S. N. A. et al., Prostaglandin E2 amplifies IL-17 production by γδ T cells during barrier inflammation. Cell Rep. 2021. 36: 109496.

Carey, M. A., Germolec, D. R., Bradbury, J. A., Gooch, R. A., Moorman, M. P., Flake, G. P., Langenbach, R. et al., Accentuated T helper type 2 airway response after allergen challenge in cyclooxygenase-1−/− but not cyclooxygenase-2−/− mice. Am. J. Respir. Crit. Care Med. 2003;167: 1509-1515.

Zeldin, D. C., Wohlford-Lenane, C., Chu, T., Bradbury, J. A., Scarbrough, P. E., Roggli, V., Langenbach, R. et al., Airway inflammation and responsiveness in prostaglandin H synthase-deficient mice exposed to bacterial lipopolysaccharide. Am. J. Respir. Crit. Care Med. 2001. 25: 457-465.

Nakata, J., Kondo, M., Tamaoki, J., Takimoto, T., Nohara, M., Yamagata, K., Nagai, A. et al., Augmentation of allergic inflammation in the airways of cyclooxygenase-2-deficient mice. Respiratory research 2005. 10: 149-156.

Card, J. W., Carey, M. A., Bradbury, J. A., Graves, J. P., Lih, F. B., Moorman, M. P., Morgan, D. L. et al., Cyclooxygenase-1 overexpression decreases basal airway responsiveness but not allergic inflammation. J. Immunol. 2006. 177: 4785-4793.

Peebles R. S. Jr., Dworski, R., Collins, R. D., Jarzeczka, K., Mitchell, D. B., Graham, B. S. and Sheller, J. R., Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice. Am. J. Respir. Crit. Care Med. 2000. 162: 676-681.

Machado, E. R., Carlos, D., Lourenço, E. V., Souza, G. E. P., Sorgi, C. A., Silva, E. V., Ueta, M. T. et al., Cyclooxygenase-derived mediators regulate the immunological control of Strongyloides venezuelensis infection. FEBS Immunol. Med. Microbiol. 2010. 59: 18-32.

Nakamura, T., Maeda, S., Horiguchi, K., Maehara, T., Aritake, K., Choi, B.-I., Iwakura, Y. et al., PGD2 deficiency exacerbates food antigen-induced mast cell hyperplasia. Nat. Commun. 2015. 6: 7514.

Buchheit, K. M., Cahill, K. N., Katz, H. R., Murphy, K. C., Feng, C., Lee-Sarwar, K., Lai, J. et al., Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. 2016. 137: 1566-1576.

Ugur, T., Sato, T., Kanamori, T., Aritake, K., Urade, Y. and Yokozeki, H., FcRI, but not FcγRI, signals induce prostaglandin D2 and E2 production from basophils. Am. J. Pathol. 2011. 179: 775-782.

Maric, J., Ravindran, A., Mazzurana, L., Van Acker, A., Rao, A., Kokkinou, E., Ekoff, M. et al., Cytokine-induced endogenous production of prostaglandin D2 is essential for human group 2 innate lymphoid cell activation. J. Allergy Clin. Immunol. 2019. 143: 2202-2214.

Henkel, F. D. R., Friedl, A., Haid, M., Thomas, D., Bouchery, T., Haimerl, P., de Los Reyes Jiménez, M. et al., House dust mite drives proinflammatory eicosanoid reprogramming and macrophage effector functions. Allergy 2019. 74: 1090-1101.

Bezençon, C., Fürholz, A., Raymond, F., Mansourian, R., Métairon, S., Le Coutre, J. and Damak, S., Murine intestinal cells expressing Tprn5 are mostly brush cells and express markers of neuronal and inflammatory cells. J. Comp. Neurol. 2008. 509: 514-525.

Gerbe, F., Van Es, J. H., Makrini, L., Brulin, B., Mellitzer, G., Robine, S., Romagnolo, B. et al., Distinct ATOH1 and Neurog3 requirements define tuft cells as a new secretory cell type in the intestinal epithelium. Cell Biol. 2011. 192: 767-780.

Oyesola, O. O., Shanahan, M. T., Kane, M., Mooney, B. W., Webb, L. M., Smitha, S., Matheson, M. K. et al., PGD2 and CRTH2 counteract Type 2 cytokine–elicited intestinal epithelial responses during helminth infection. J. Exp. Med. 2021. 218: e20202178.

Wu, L., Lin, Q., Ma, Z., Chowdhury, F., Mazumder, M. H. and Du, W., Mesenchymal COX2-derived PGD2 activates an ILC2-treg axis to promote proliferation of normal and malignant HSPCs. Blood 2019. 134(Suppl 1): 1208.

Kim, J., Yang, P., Suraokar, M., Sabichi, A. L., Llansa, N. D., Mendoza, G., Subbarayan, V. et al., Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res. 2005. 65: 6189-6198.

Petitpier, R., The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses. Br J. Pharmacol. 2008. 153(Suppl 1): S191-S199.
chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor Cth2. J. Exp. Med. 2001. 193: 255–262.

78 Wojno, E. D., Monticelli, L. A., Tran, S. V., Alenghat, T., Osborne, L. C., Thome, J. J., Willis, C. et al., The prostaglandin D2 receptor CTH2 regulates accumulation of group 2 innate lymphoid cells in the inflamed lung. Mucosal Immunol. 2015. 8: 1313–123.

79 Monneret, G., Gravel, S., Diamond, M., Rokach, J. and Powell, W. S., Prostaglandin D2 is a potent chemotaxant for human eosinophils that acts via a novel DP receptor. Blood 2001. 98: 1942–1948.

80 Yoshimura-Uchiyama, C., Iikura, M., Yamaguchi, M., Nagase, H., Ishii, A., Matsushima, K., Yamamoto, K. et al., Differential modulation of human basophil functions through prostaglandin D2 receptors DP and chemotactic receptor-homologous molecule expressed on Th2 cells/DP2. Clin. Exp. Allergy 2004. 34: 1283–1290.

81 Xue, L., Salimi, M., Panse, I., Mjöberg, J. M., McKenzie, A. N., Spits, H., Klenerman, P. et al., Prostaglandin D2 activates group 2 innate lymphoid cells through chemotactic receptor-homologous molecule expressed on TH2 cells. J. Allergy Clin. Immunol. 2014. 133: 1184–1194.

82 Berair, R., Gomem, S., Singapuri, A., Hartley, R., Laurencon, M., Bacher, G., Holzhauser, B. et al., Late-breaking abstract: effect of QAW039, an oral prostaglandin D2 receptor (DP2/CTHR2) antagonist, upon bronchial epithelial integrity in treatment-resistant asthma in a randomized, placebo controlled study. Eur. Respir. J. 2015. 46: OA290.

83 Stinson, S. E., Amran, Y. and Brightling, C. E., D prostanoid receptor 2 (chemotactic receptor-homologous molecule expressed on TH2 cells) protein expression in asthmatic patients and its effects on bronchial epithelial cells. J. Allergy Clin. Immunol. 2015. 135: 395–406.

84 Chinato, K., Takagi, K., Iiyama, K., Fujiyama, Y., Fukumoto, S., Eguchi, N., Urade, Y. et al., Central prostaglandin D2 stimulates food intake via the neuropeptide Y system in mice. FEBS Lett. 2008. 582: 679–684.

85 Bryan Smith, J., Silver, M. J., Ingerman, C. M. and Kocsis, J. J., Prostaglandin D2 inhibits the aggregation of human platelets. Thromb. Res. 1974. 5: 291–299.

86 Mills, D. C. B. and Macfarlane, D. E., Stimulation of human platelet adenylate cyclase by prostaglandin D2. Thromb. Res. 1974. 5: 401–412.

87 Maher, S. A., Birrell, M. A., Adcock, J. J., Wortley, M. A., Dubuis, E. D., Bonvini, S. J., Grace, M. S. et al., Prostaglandin D2 and the role of the DP1, DP2 and TP receptors in the control of airway reflex events. Eur. Respir. J. 2015. 45: 1108–1118.

88 Nagamachi, M., Sakata, D., Kabashima, K., Furuyashiki, T., Murata, T., Segi-Nishida, E., Soostrupa, K. et al., Facilitation of Th1-mediated immune response by prostaglandin E receptor EP1. J. Exp. Med. 2007. 204: 2865–2874.

89 Kaisar, M. M. M., Ritter, M., Del Fresno, C., Jónasdóttir, H. S., van der Ham, A. J., Pelgrom, L. R., Schramm, G. et al., Dectin-1/2-induced autocrine PGF2 signaling licenses dendritic cells to prime Th2 responses. PLoS Biol. 2018. 16: e2005504.

90 Hirata, T. and Narumiya, S., Chapter five - prostanoids as regulators of innate and adaptive immunity. In: Alt, F. W. (Ed.), Advances in immunology, vol. 116. Academic Press, Cambridge, MA, 2012. p. 143–174.

91 Yao, C. and Narumiya, S., Prostaglandin-cytokine crosstalk in chronic inflammation. Br. J. Pharmacol. 2019. 176: 337–354.

92 Marc, J., Ravindran, A., Mazzarola, L., Björklund, Å. K., Van Acker, A., Rao, A., Friberg, D. et al., Prostaglandin E2 suppresses human group 2 innate lymphoid cell function. J. Allergy Clin. Immunol. 2018. 141: 1761–1773.

93 Duffin, R., O’Connor, R. A., Crittenden, S., Forster, T., Yu, C., Zheng, X., Smyth, D. et al., Prostaglandin E2-constrains systemic inflammation through an innate lymphoid cell–IL-22 axis. Science 2016. 351: 1333–1338.

94 Crittenden, S., Goep, M., Pollock, J., Robb, C. T., Smyth, D. J., Zhou, Y., Andrews, R. et al., Prostaglandin E2 promotes intestinal inflammation via inhibiting microbiota-dependent regulatory T cells. bioRxiv. 2020. https://doi.org/10.1101/2020.07.12.199513.

95 Luschning-Schralt, P., Sturm, E. M., Konya, V., Philoposse, S., Marsche, G., Pröhlich, E., Samberger, C. et al., EP4 receptor stimulation down-regulates human eosinophil function. Cell. Mol. Life Sci. 2011. 68: 3573–3587.

96 Sturm, E. M., Schralt, P., Schuligoi, R., Konya, V., Sturm, G. J., Lippe, I. T., Peskar, B. A. et al., Prostaglandin E2 inhibits eosinophil trafficking through E-prostanoid 2 receptors. J. Immunol. 2008. 181: 7273–7283.

97 Konger, R. L., Brouxhon, S., Parillo, S., VanBuskirk, J. and Pentland, A. P., The EP3 receptor stimulates ceramide and diacylglycerol release and inhibits growth of primary keratinocytes. Exp. Dermatol. 2005. 14: 914–922.

98 Honda, T., Matsuoka, T., Ueta, M., Kabashima, K., Miyachi, Y. and Narumiya, S., Prostaglandin E2–EP3 signaling suppresses skin inflammation in murine contact hypersensitivity. J. Allergy Clin. Immunol. 2009. 124: 809–818.

99 Nunikata, T., Yamane, H., Segi, E., Matsuoaka, T., Sugimoto, Y., Tanaka, S., Tanaka, H. et al., Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat. Immunol. 2005. 6: 524–531.

100 Akaba, T., Kamiya, K., Suzaki, I., Kozaki, Y., Tamaoki, J. and Rubin, B. K., Activating prostaglandin E2 receptor subtype EP4 increases secreted mucin from airway goblet cells. PLoS Pathog. 2018. 48: 117–123.

101 Zhou, Y., Wang, W., Zhao, C., Wang, Y., Wu, H., Sun, X., Guan, Y. et al., Prostaglandin E2 inhibits group 2 innate lymphoid cell activation and allergic airway inflammation through E-prostanoid 4-cyclic adenosine monophosphate signaling. Front. Immunol. 2018. 9: 501.

102 Torres-Atencio, I., Ainsua-Enrich, E., de Mora, F., Picado, C. and Martin, M., Prostaglandin E2 prevents proinflammatory-induced human mast cell activation through prostaglandin receptors EP2 and EP4. PLoS One 2014. 9: e110870.

103 Kay, L. J., Yeo, W. W. and Peachell, P. T., Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation. Br. J. Pharmacol. 2006. 147: 707–713.

104 Laan, L. C., Williams, A. R., Stavenhagen, K., Giera, M., Kooij, G., Vlasakov, I., Kalay, H. et al., The whipworm (Trichuris suis) secretes prostaglandin E2 to suppress proinflammatory properties in human dendritic cells. FASEB J. 2017. 31: 719–731.

105 Dorris, S. L. and Peebles, R. S., PGI2 as a regulator of inflammatory diseases. Mediators Inflamm. 2012. 2012: 926968.

106 Jaffar, Z., Wan, K. S. and Roberts, K., A key role for prostaglandin l2 in limiting lung mucosal Th2, but not Th1, responses to inhaled allergen. J. Immunol. 2002. 169: 5997–6004.

107 Jaffar, Z., Ferrini, M. E., Buford, M. C., FitzGerald, G. A. and Roberts, K., Prostaglandin l2–IP signaling blocks allergic pulmonary inflammation by preventing recruitment of CD4+ Th2 cells into the airways in a mouse model of asthma. J. Immunol. 2007. 179: 6193–6203.

108 Oida, H., Namba, T., Sugimoto, Y., Ushikubi, F., Ohishi, H., Ichikawa, A. and Narumiya, S., In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs. Br. J. Pharmacol. 1995. 116: 2828–2837.

109 Toki, S., Goleniewska, K., Huckabbe, M. M., Zhou, W., Newcomb, D. C., FitzGerald, G. A., Lawson, W. E. et al., PGI2 signaling inhibits antigen uptake and increases migration of immature dendritic cells. J. Leukoc. Biol. 2013. 94: 77–88.
ways during acute antigen challenge. Inflammatory cytokine production and T cell stimulatory function of dendritic cells and T cells and regulates acquired immunity. Prostaglandins Other Lipid Mediat. 2015. 109: 7–21.

Zhou, W., Blackwell, T. S., Goleniewska, K., O’Neal, J. F., FitzGerald, G. A., Lucitc, M., Breyer, R. M., et al., Prostaglandin I2 analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cells. J. Leukoc. Biol. 2007. 81: 809–817.

Wong, T.-H., Gonen, S., Shen, H.-H., Lin, C.-T.-Y., Shen, S.-L., and Suen, J.-L., Dendritic cells treated with a prostaglandin I2 analog, iloprost, promote antigen-specific regulatory T cell differentiation in mice. Int. Immunopharmacol. 2020. 79: 10610.

Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto, Y., Ichikawa, A., et al., Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature. 1979: 187: 678–682.

Zhou, W., Hashimoto, K., Goleniewska, K., O’Neal, J. F., Ji, S., Blackwell, T. S., Fitzgerald, G. A., et al., Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J. Immunol. 2007. 178: 702–710.

Sturm, E. M., Schuligoi, R., Konya, V., Sturm, G. J., and Heinemann, A., Inhibitory effect of prostaglandin I2 on bone marrow kinetics of eosinophils in the guinea pig. J. Leukoc. Biol. 2011. 90: 285–291.

Tsai, Y.-J., Hao, S.-P., Chen, C.-L., and Wu, W.-B., Thromboxane A2 regulates CXCL1 and CXCL8 chemokine expression in the nasal mucosa-derived fibroblasts of chronic rhinosinusitis patients. PLoS One 2016. 11: e0158438.

Kabashima, K., Murata, T., Tanaka, H., Matsuoka, T., Sakata, D., Yoshida, N., Katagiri, K., et al., Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat. Immunol. 2003. 4: 694–701.

Nakahata, N., Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol. Ther. 2008. 118: 18–35.

Brune, K., Glatt, M., Kälin, H., and Peskar, B. A., Pharmacological control of prostaglandin and thromboxane release from macrophages. Nature 1978. 274: 261–263.

Joo, M., and Sadikot, R. T., PGD synthase and PGD2 in immune responses. Mediators Inflamm. 2012. 2012: S03128.

Murray, J. J., Tonnek, A. B., Brash, A. R., Roberts, L. J., 2nd, Gosset, P., Workman, R., Capron, A., et al., Release of prostaglandin D2 into human airways during acute antigen challenge. N. Engl. J. Med. 1986. 315: 800–804.

Fajt, M. L., Gelhaus, S. L., Freeman, B., Uvalle, C. E., Trudeau, J. B., Holguin, F., and Wenzel, S. E., Prostaglandin D2 pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J. Allergy Clin. Immunol. 2013. 131: 1504–1512.
Prostaglandin E2 signal mediated by receptor subtype EP2 promotes IgE production in vivo and contributes to asthma development. Sc. Rep. 2016. 6: 20505.

Lee, K., Lee, S. H. and Kim, T. H., The biology of prostaglandins and their role as a target for allergic airway disease therapy. Int. J. Mol. Sci. 2020. 21: 1851.

Brattig, N. W., El-Haroun, H., Upholt, A., Hoerauf, A. and Böttner, D. W., Identification of the lipid mediator prostaglandin E2 in tissue immune cells of humans infected with the filaria Onchocerca volvulus. Acta Trop. 2009. 112: 231–235.

Conder, G. A., Mayberry, I. F., Bristol, J. R., Castro, G. A., Lee, B. L., Kratzer, D. D., Polz, S. D. et al., Effects of PGE1 or PGE2 and/or acetazolamide on expulsion of Nippostrongylus brasiliensis from rats. Prostaglandins. 1987. 34: 817–827.

Hilkens, C. M., Snijders, A., Snijdjewint, F. G., Wierenga, E. A. and Kapsenberg, M. L., Modulation of T-cell cytokine secretion by accessory cell-derived products. Eur. Respir. J. Suppl. 1996. 22: 90s–94s.

Kaliinski, P., Hilkens, C. M., Snijders, A., Snijdjewint, F. G. and Kapsenberg, M. L., IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J. Immunol. 1997. 159: 25–38.

Kuroda, E. and Yamashita, U., Mechanisms of enhanced macrophage- mediated prostaglandin E2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice. J. Immunol. 2003. 170: 757–764.

Shea-Donohue, T., Sullivan, C., Finkelman, F., Madden, K., Morris, S., Goldhill, J., Piñero-Carrero, V. et al., The role of IL-4 in heligmosomoides polyergus-induced alterations in murine intestinal epithelial cell function. J. Immunol. 2001. 167: 2234–2239.

Gurumurthy, C. B. and Lloyd, K. C. K., Generating mouse models for biomedical research: technological advances. Dis. Model Mech. 2019. 12: dmm029462.

Camacho, M., Rodríguez, C., Guadali, A., Alcolea, S., Orriols, M., Escudero, J.-R., Martínez-González, J. et al., Hypoxia upregulates PGI-synthase and increases PGI, release in human vascular cells exposed to inflammatory stimuli. J. Lipid Res. 2011. 52: 720–731.

El-Haroun, H., Clarke, D. L., Deacon, K., Bradbury, D., Clayton, A., Sutcliffe, A. and Knox, A. J., IL-beta, BK, and TGF-beta1 antagonise PGF-/mediated CAMF formation in human pulmonary artery smooth muscle cells by multiple mechanisms involving p38 MAP kinase and PKA. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008. 294: L553–L562.

Hammarström, S. and Falardeau, P., Resolution of prostaglandin endoperoxide synthase and thromboxane synthase of human platelets. Proc. Natl. Acad. Sci. U.S.A. 1977. 74: 3691–3695.

Bunting, S., Moncada, S. and Vane, J. R., The prostacyclin-thromboxane a 2 balance: pathophysiological and therapeutic implications. Br. Med. Bull. 1983. 39: 271–276.

Takahashi, Y., Tokuoka, S., Masuda, T., Hirano, Y., Nagao, M., Tanaka, H., Inagaki, N. et al., Augmentation of allergic inflammation in prostaglandin IP receptor deficient mice. Br. J. Pharmacol. 2002. 137: 315–322.
Fasciola hepatica.

Magalhães, K. G., Luna-Gomes, T., Mesquita-Santos, F., Corrêa, R., Assunção, L. S., Atella, G. C., Wellers, P. F. et al., Schistosomal lipids activate human eosinophils via toll-like receptor 2 and PGD2 Receptors: 15-LO role in cytokine secretion. Front. Immunol. 2019. 9: 3161.

Ramawamy, K., Kumar, P. and He, Y. X., A role for parasite-induced PGE2 in IL-10-mediated host immunoregulation by skin stage schistosomula of Schistosoma mansoni. J. Immunol. 2000. 165: 4567–4574.

Salafsky, B. and Fusco, A. C., Schistosoma mansoni: a comparison of secreted vs nonsecreted eicosanoids in developing schistosomulae and adults. Exp. Parasitol. 1987. 64: 361–367.

Sommer, A., Rickert, R., Fischer, P., Steinhart, H., Walter, R. D. and Liebau, E., A dominant role for extracellular glutathione S-transferase from Onchocerca volvulus is the production of prostaglandin D2. Infect. Immun. 2003. 71: 3603–3606.

Brattig, N. W., Schwohl, A., Rickert, R. and Böttner, D. W., The filarial parasite Onchocerca volvulus generates the lipid mediator prostaglandin E2. Microbes Infect. 2006. 8: 873–879.

Giera, M., Kaisar, M. M. M., Derks, R. J. E., Steenvoorden, E., Kruize, Y. C. M., Hokke, C. H., Yazdanbakhsh, M. et al., The Schistosoma mansoni lipidome: leads for immunomodulation. Anal. Chem. Acta 2018. 1037: 107–118.

Fusco, A. C., Salafsky, B. and Kevin, M. B., Schistosoma mansoni: eicosanoid production by cercariae. Exp. Parasitol. 1985. 59: 44–50.

Salafsky, B. and Fusco, A. C., Schistosoma mansoni: cecalial eicosanoid production and penetration response inhibited by esculetin and ibuprofen. Exp. Parasitol. 1985. 60: 73–81.

Liu, L. X., Buhlmann, J. E. and Wellers, P. F., Release of prostaglandin E2 by microfilariae of Wuchereria bancrofti and Brugia malayi. Am. J. Trop. Med. Hyg. 1992. 46: 520–523.

Liu, L. X. and Wellers, P. F., Intravascular filarial parasites inhibit platelet aggregation. Role of parasite-derived prostanoids. J. Clin. Invest. 1992. 89: 1113–1120.<bib>.

Bandeira-Melo, C., Serra, M. F., Díaz, B. L., Cordeiro, R. S., Silva, P. M., Lenzi, H. L., Baklhe, Y. S. et al. Cyclooxygenase-2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia. J. Immunol. 2000. 164: 1029–1036.

Biserova, N. M., Kutyrev, I. A. and Malakhov, V. V., The tapeworm Diphylobothrium dendriticum (Cestoda) produces prostaglandin E2, a regulator of host immunity. Dokl. Biol. Sci. 2011. 441: 367–369.

Ali, S. F., Joachim, A. and Daugschies, A., Eicosanoid production by adult Fasciola hepatica and plasma eicosanoid patterns during fasciolosis in sheep. Int. J. Parasitol. 1999. 29: 743–748.

Ittiprasert, W., Mann, V. H., Karinshak, S. E., Coghlan, A., Rinaldi, G., Sankaranarayanan, G., Chaidee, A. et al., Programmed genome editing of the omega-1 ribonuclease of the blood fluke, Schistosoma mansoni. elife 2019. 8: e41337.

Arunsan, P., Ittiprasert, W., Smut, M. J., Cochran, C. J., Mann, V. H., Chaiyadet, S., Karinshak, S. E. et al., Programmed knockout mutation of liver fluke granulin attenuates virulence of infection-induced hepato-lobar morbidity. elife 2019. 8: e41463.

Wang, J., Paz, C., Padalino, G., Coghlan, A., Lu, Z., Gradianu, I., Collins, J. N. R. et al., Large-scale RNAi screening uncovers therapeutic targets in the parasite Schistosoma mansoni. Science. 2020. 369: 1649–1653.

Chiba, T., Ueki, S., Ito, W., Kato, H., Kamada, R., Takeda, M., Kayaba, H. et al., The opposing role of two prostaglandin D2 receptors, DP and CRTH2, in human eosinophil migration. Ann. Allergy Asthma Immunol. 2011. 106: 511–517.

White, C., Wright, A. and Brightling, C., Fevipiprant in the treatment of asthma. Expert Opin. Invest. Drugs 2018. 27: 199–207.

Arimura, A., Yasui, K., Kishino, J., Asanuma, F., Hasegawa, H., Kakudo, S., Ohtani, M. et al., Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J. Pharmacol. Exp. Ther. 2001. 298: 411–419.

Ishizuka, T., Matsu, T., Okamoto, Y., Ohta, A. and Shichijo, M., Ramatroban (BAY u 3405): a novel dual antagonist of TXA2 receptor and CRTH2, a newly identified prostaglandin D2 receptor. Cardiovasc. Drug Rev. 2004. 22: 71–90.

Terada, N., Yamakoshi, T., Hasegawa, M., Tanikawa, H., Nagata, H., Mae, S., K.-I., Konno, A. et al., Effect of a thromboxane A2 receptor antagonist ramatroban (BAY u 3405), on inflammatory cells, chemical mediators and non-specific nasal hyperreactivity after allergen challenge in patients with perennial allergic rhinitis. Allergol. Int. 1998. 47: 59–67.

Petittper, R., Hansel, T. T. and Armer, R., Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat. Rev. Drug Discovery 2007. 6: 313–325.

Chang, J. E., Doherty, T. A., Baum, R. and Broide, D., Prostaglandin D2 regulates human type 2 innate lymphoid cell chemotaxis. J. Allergy Clin. Immunol. 2014. 133: 899–901.

Sugimoto, H., Shichijo, M., Iino, T., Manabe, Y., Watanabe, A., Shima-Matsuda, M., Gantner, F. et al., An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u 3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J. Pharmacol. Exp. Ther. 2003. 305: 347–352.

Petittper, R., Vinall, S. L., Xue, L., Speight, G., Townsend, E. R., Gazi, L., Whelan, C. J. et al., Pharmacologic profile of OC000459, a potent, selective, and orally active D prostaglandin receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils. J. Pharmacol. Exp. Ther. 2012. 340: 473–482.

Liu, J., Li, A.-R., Wang, Y., Johnson, M. G., Su, Y., Shen, W., Wang, X. et al., Discovery of AMG 853, a CRTH2 and DP dual antagonist. ACS Med. Chem. Lett. 2011. 2: 326–330.

Busse, W. W., Wenzel, S. E., Melzner, E. O., Kerwin, E. M., Liu, M. C., Zhang, N., Chon, Y. et al., Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J. Allergy Clin. Immunol. 2013. 131: 339–345.

Brightling, C. E., Gega, M., Inoue, H., Li, J., Maspero, J., Wenzel, S., Mastra, S. et al., Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials. Lancet Respir. Med. 2021. 9: 43–56.

Brightling, C. E., Brusselle, G. and Altman, P., The impact of the prostaglandin D2 receptor 2 and its downstream effects on the pathophysiology of asthma. Allergy 2020. 75: 761–768.

Sykes, D. A., Bradley, M. E., Riddy, D. M., Willard, E., Reilly, J., Miah, A., Bauer, C. et al., Fevipiprant (QAW039), a slowly dissociating CRTH2 antagonist with the potential for improved clinical efficacy. Mol. Pharmacol. 2016. 89: 593–605.

Stebbins, K. J., Broadhead, A. R., Correa, L. D., Scott, J. M., Truong, Y. P., Stearns, B. A., Hutchinson, J. H. et al., Therapeutic efficacy of AM156, a novel prostaglandin DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation. Eur. J. Pharmacol. 2010. 638: 142–149.

Takahashi, G., Tanaka, H., Higuchi, N., Ikeda, M., Inagaki, N. and Shichijo, M., The potential role of prostaglandin D2 in nasal congestion observed in a guinea pig model of allergic rhinitis. Int. Arch. Allergy Immunol. 2012. 158: 359–368.
207 Hirano, Y., Shichijo, M., Ikeda, M., Kitaura, M., Tsuchida, J., Asanuma, F., Yanagimoto, T. et al., Prostanoid DP receptor antagonists suppress symptomatic asthma-like manifestation by distinct actions from a glucocorticoid in rats. *Eur. J. Pharmacol.* 2011. 666: 233–241.

208 Shichijo, M., Arimura, A., Hirano, Y., Yasui, K., Suzuki, N., Deguchi, M. and Abraham, W. M., A prostaglandin D2 receptor antagonist modifies experimental asthma in sheep. *Clin. Exp. Allergy* 2009. 39: 1404–1414.

209 Uller, L., Mathiesen, J. M., Alenmyr, L., Korsgren, M., Ulven, T., Högb erg, T., Andersson, G. et al., Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. *Respir. Res.* 2007. 8: 16.

210 Horak, F., Zieglmayer, P., Zieglmayer, R., Lemell, P., Collins, L. P., Hunter, M. G., Steiner, J. et al., The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. *Allergy* 2012. 67: 1572–1579.

211 Barnes, N., Pavord, I., Chuchalin, A., Bell, J., Hunter, M., Lewis, T., Parker, D. et al., A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. *Clin. Exp. Allergy* 2012. 42: 38–48.

212 Pettipher, R., Hunter, M. G., Perkins, C. M., Collins, L. P., Lewis, T., Baillet, M., Steiner, J. et al., Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. *Allergy* 2014. 69: 1223–1232.

213 Singh, D., Cadden, P., Hunter, M., Pearce Collins, L., Perkins, M., Pettipher, R., Townsend, E. et al., Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. *Eur. Respir. J.* 2013. 41: 46–52.

214 Gonem, S., Berair, R., Singapuri, A., Hartley, R., Laurencin, M. F. M., Bacher, G., Holzhauer, B. et al., Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. *Lancet Respir. Med.* 2016. 4: 699–707.

215 Willard, L., Brown, Z., Owen, C. and Dubois, G., Characterization QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists. *Eur. Respir. J.* 2014. 44: P4072.

216 Epenbenke, V. J., Vets, E., Gheyle, L., Osuntokun, W., Larbig, M., Neelakantham, S., Sandham, D. et al., Pharmacokinetics, safety, and tolerability of fevipiprant (QAW039), a novel CRTH2 receptor antagonist: results from 2 randomized, phase 1, placebo-controlled studies in healthy volunteers. *Clin. Pharmacol. Drug Dev.* 2016. 5: 306–313.

217 Laidlaw, T. M. and Boyce, J. A., Aspirin-exacerbated respiratory disease—new prime suspects. *N. Engl. J. Med.* 2016. 374: 484–488.

**Abbreviations:** AA: arachidonic acid · COX: chemoattractant receptor-homologous molecule expressed on Th2 cells, CRTH2 cyclooxygenase · CYP: cytochrome P450 epoxygenase · HES: helminth excretory secretory products · HDM: house dust mite · PLA: phospholipase · PG: prostaglandin · PGDS: prostaglandin D synthase · PGES: prostaglandin E synthase · EP: prostaglandin E2 receptor · PGFS: prostaglandin F synthase · PGIS: prostaglandin I synthase · IP: prostaglandin I2 receptor · Th2: T helper type 2 · TXA2: thromboxane A2 · TXAS: thromboxane A synthase · TP: thromboxane receptor

Full correspondence: Dr. Elia D. Tait Wojno, University of Washington, 750 Republican St., Rm. 550, Seattle, WA, 98117, USA
e-mail: etwojno@uw.edu

Received: 25/11/2020
Revised: 11/5/2021
Accepted: 13/8/2021
Accepted article online: 0/0/2021